1,721,150 research outputs found

    The evidence for antimuscarinic agents in female mixed urinary incontinence

    No full text
    Antimuscarinic agents are the most commonly used treatments for overactive bladder (OAB) syndrome where they reduce urgency, frequency, and urge incontinence. Despite few studies investigating the effects of antimuscarinic agents on mixed urinary incontinence (MUI), awareness is increasing about their value as first-line treatments for patients with MUI (combination of OAB wet and stress urinary incontinence). Evidence suggests that they are as effective in patients with urgency-predominant MUI as they are in OAB, resulting in significant reductions in urgency episodes, urinary frequency, and incontinence. (c) 2006 Published by Elsevier B.V. on behalf of European Association of Urology

    Going Beyond Counting First Authors in Author Co-citation Analysis

    Full text link
    The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed

    Tolterodine for the treatment of overactive bladder

    No full text
    Background: The overactive bladder syndrome is a common condition affecting similar to 12% of men and women. It is extremely disturbing with a great impact on quality of life. Its treatment involves a combination of behavioural and pharmacological therapy. The latter includes antimuscarinic drugs such as tolterodine. Objective: To review the safety and efficacy of tolterodine in the treatment of overactive bladder in comparison with other available antimuscarinic agents. Methods: A Pubmed search was carried out differentiating randomised, clinical trials; longitudinal, retrospective studies; and metanalysis on the use of tolterodine for overactive bladder treatment. In the comparison with other antimuscarinic agents, only randomised, clinical trials were considered. Results/conclusion: Tolterodine is available as immediate- or extended-release formulations. It has been extensively evaluated with long-term, randomised trials for safety and efficacy showing a significant improvement in overactive bladder symptoms with an excellent tolerability profile
    corecore